Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for the management of symptoms associated with knee osteoarthritis (OA).ReNu is a cryopreserved, amniotic suspension allograft (ASA) developed for managing symptomatic knee osteoarthritis.ReNu consists of amniotic fluid cells and micronized amniotic membrane and contains cellular, growth factor, and extracellular mat ...

Amgen Inc. (NASDAQ:AMGN) is one of the best value stocks in Goldman Sachs’ portfolio. On September 18, Piper Sandler analyst David Amsellem maintained a Buy rating on Amgen and with an unchanged price target of $342. A few weeks before this update, William Blair analyst Matt Phipps, who also rates the stock a Buy, highlighted the importance of the company’s upcoming FORTITUDE-102 study results, which combine bemarituzumab with chemotherapy and Opdivo. A favorable outcome for this study could substantially ...

Exelixis, Inc. (NASDAQ:EXEL) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 17, Morgan Stanley raised the stock’s price target to $50 from $46, while maintaining an Overweight rating for its shares. Morgan Stanley Maintains Overweight Rating For Exelixis, Inc. (EXEL), Price Target Raised To $50 Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels In a research note to investors, the analyst noted that Zanzalintinib presents a significan ...

Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly ...

The major U.S. index futures are currently pointing to a higher open on Friday, with stocks likely to regain ground after trending lower over the past few sessions.Traders may look to pick up stocks at relatively reduced levels following the recent pullback, which partly reflected concerns about valuations and the near-term outlook for the artificial intelligence trade.The futures saw further upside following the release of a closely watched Commerce Department report showing consumer prices increased in l ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and then buying some of the stock in the $40s.On Sept. 24, RBC Capital analyst Logan Reich reiterated Dutch Bros with an Outperform and maintained a price target of $85.American Bitcoin Corp (NASDAQ: ABTC) is a “total spec,” Cramer said.As per the recent news, American Bitcoin, on Thursday, named KPMG as new auditor.Recursion Pharmaceuticals (NASDAQ: RXRX) has been a “bad stock. We need to ...

Lexaria Bioscience (NASDAQ:LEXX) was trading lower after the drug delivery platform announced a sale of 2,666,667 shares, par value $0.001 per share, at $1.50 per share in a registered direct offering. Gross proceeds are expected to be ~$4.0M. Shares were ...

融资活动 - 公司通过注册直接发行和私募配售方式融资 注册直接发行以每股1.50美元价格发行2,666,667股普通股 同时私募配售发行可认购2,666,667股普通股的认股权证 认股权证行权价为每股1.37美元且立即生效 有效期五年 [1] - 本次融资总收益预计约为400万美元 扣除承销商费用及其他发行费用前 净收益将用于营运资金及其他一般公司用途 [2] - 融资交易预计于2025年9月29日左右完成 需满足常规交割条件 [1] 发行结构 - 普通股发行依据S-3表格货架注册声明(文件号333-284407) 该注册声明于2025年1月30日获美国证券交易委员会宣布生效 发行仅通过包含招股说明书补充文件的有效注册声明进行 [3] - 认股权证及其对应普通股依据证券法第4(a)(2)条及D条例发行 未在证券法或州证券法下注册 因此在美国不得公开销售 除非符合有效注册声明或注册豁免要求 [4] 公司技术平台 - DehydraTECH是公司专利药物递送技术平台 通过口服递送改善药物吸收方式 该技术已证明可提高生物吸收度 减少副作用 并更有效穿透血脑屏障 [6] - 公司拥有50项授权专利及多项全球专利申请 运营持牌内部研究实验室 [6] 中介机构与信息披露 - H.C. Wainwright & Co担任本次发行独家配售代理 招股说明书补充文件及相关招股说明书可在美国证券交易委员会网站获取 或通过该机构联系方式获取 [2][3]

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. (NASDAQ:PSTV) is one of the top performers on Thursday. Shares of Plus Therapeutics soared by 39.29 percent on Thursday to finish at $0.5630 apiece as investors cheered a national coverage agreement with UnitedHealth Group Inc. Under the partnership, Plus Therapeutics Inc. (NASDAQ:PSTV), through its subsidiary CNSide Diagnostics LLC, will provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory ...

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. PepGen Inc. (NASDAQ:PEPG) is one of the top performers on Thursday. Shares of PepGen soared by 121.05 percent on Thursday to end at $5.88 apiece as investors cheered stellar results from its clinical trial of an experimental drug to treat myotonic dystrophy type 1 (DM1). In a statement, PepGen Inc. (NASDAQ:PEPG) said it saw a 53.7 percent correction in the key genetic error that drives the disease in patients taking 15 mg/kg of t ...